readthroughSign in
CompanyLYELNasdaqSouth San Francisco, CA

Lyell Immunopharma, Inc.

Lyell develops next-generation CAR T-cell therapies for hematologic malignancies and solid tumors.

SCHEDULE 13G/ANov 10Latest SEC filing
Nov 4Latest story